Loading…
Enovis Corporation is projected to rise to $24.97 by 2027, a +8% move from its current price of $23.11. ENOV is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $22.34 | $23.12 | $23.92 | +0.04% |
| May 30 | $22.03 | $23.13 | $24.28 | +0.08% |
| May 31 | $21.80 | $23.14 | $24.55 | +0.11% |
| Jun 1 | $21.61 | $23.15 | $24.79 | +0.15% |
| Jun 2 | $21.45 | $23.15 | $25.00 | +0.19% |
| Jun 3 | $21.30 | $23.16 | $25.19 | +0.23% |
| Jun 4 | $21.16 | $23.17 | $25.37 | +0.27% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $21.16 | $23.17 | $25.37 | +0.27% |
| Week 2 | $20.44 | $23.23 | $26.41 | +0.53% |
| Week 3 | $19.91 | $23.29 | $27.25 | +0.80% |
| Week 4 | $19.49 | $23.36 | $28.00 | +1.07% |
| Week 5 | $19.12 | $23.42 | $28.68 | +1.33% |
| Week 6 | $18.81 | $23.48 | $29.32 | +1.60% |
| Week 7 | $18.52 | $23.54 | $29.92 | +1.87% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Enovis Corporation (ENOV) is a healthcare company focused on developing clinically differentiated medical technology solutions for patients in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions.
The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients.
The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
Enovis Corporation (ENOV) is a healthcare company focused on medical technology and devices. It is currently priced at $24.19 per share, has a market capitalization of $1.39B, and is ranked 2286 by market cap. The near-term forecast indicates a neutral stance with an average price of $24.19 in 2026, a low of $21.46, and a high of $32.65, with an ROI of 0 and sentiment NEUTRAL.
Longer-term forecasts point to bullish growth, with 2030 average price of $31.12 (ROI 28.6), 2040 average of $67.89 (ROI 180.7), and 2050 average of $132.98 (ROI 449.7).
A major floor 15.5% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.7% away) — a key level to hold.
The nearest ceiling, 17.9% above — a clean break opens room to run.
A major ceiling 25.7% above — clearing it would confirm fresh momentum.
Key ENOV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ENOV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $24.53 | Sell | $24.20 | Sell |
| MA 10 | $24.98 | Sell | $24.63 | Sell |
| MA 20 | $24.81 | Sell | $24.72 | Sell |
| MA 50 | $24.06 | Sell | $24.45 | Sell |
| MA 100 | $23.97 | Sell | $24.90 | Sell |
| MA 200 | $26.99 | Sell | $27.08 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.11 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -106.43 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.26 | Sell |
| ROC (12) | -12.86 | Sell |
| Bollinger %B (20,2) | 0.16 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.19 | Buy |
| Awesome (5,34) | -0.18 | Sell |
| Ultimate (7,14,28) | 41.77 | Neutral |
| Momentum (10) | -2.88 | Sell |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 23.69 | Sell |
| ADX (14) | 10.01 | Neutral |
| ATR (14) | 0.86 | Info |
The near-term technical picture is neutral. RSI14 is 50, with the 50-day simple moving average at $24.03 and the 200-day simple moving average at $27.04. Price is trading around the mid area of these indicators, suggesting balanced momentum. The 30-day range spans from $19.22 to $30.45, with support at $22.49 and resistance at $27.25.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $21.46 | $23.11 | $31.26 | 0% | Neutral | |
| $19.32 | $24.97 | $34.47 | +8% | Neutral | |
| $20.04 | $26.84 | $38.68 | +16% | Neutral | |
| $18.81 | $25.94 | $38.68 | +12% | Neutral | |
| $20.54 | $29.08 | $44.61 | +26% | Bullish | |
| $24.07 | $34.91 | $54.91 | +51% | Bullish | |
| $26.32 | $39.06 | $62.81 | +69% | Bullish | |
| $28.01 | $42.47 | $69.69 | +84% | Bullish | |
| $26.58 | $41.14 | $68.77 | +78% | Bullish | |
| $25.63 | $40.46 | $68.81 | +75% | Bullish | |
| $36.26 | $62.70 | $114.54 | +171% | Bullish | |
| $60.00 | $122.11 | $247.35 | +428% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $21.46 | $23.11 | $27.11 | +0.00% |
| June 2026 | $19.43 | $22.94 | $27.83 | -0.72% |
| July 2026 | $20.04 | $23.92 | $29.51 | +4.26% |
| August 2026 | $20.03 | $24.10 | $30.11 | +0.75% |
| September 2026 | $19.53 | $23.66 | $29.87 | -1.81% |
| October 2026 | $19.85 | $24.20 | $30.84 | +2.28% |
| November 2026 | $20.23 | $24.80 | $31.87 | +2.48% |
| December 2026 | $19.58 | $24.15 | $31.26 | -2.65% |
Click any year to see its month-by-month ENOV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ENOV to range from $21.46 to $31.26 through 2026. The $23.11 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The ENOV price prediction for 2027 points to an average of $24.97 (low $19.32, high $34.47) — a potential gain of +8% on today's $23.11. Price action looks broadly range-bound.
In 2028, ENOV is projected to trade between $20.04 and $38.68, averaging $26.84 — a potential gain of +16% from today's $23.11. That is up +7% on the projected 2027 average. A consolidation phase looks the most probable path here.
Enovis Corporation's 2029 outlook centres on $25.94, within a $18.81 to $38.68 range. That is -3% versus the projected 2028 average. That marks a +12% change versus current levels. Price action looks broadly range-bound.
By 2030, ENOV could reach as high as $44.61, with a base case around $29.08 and support toward $20.54 — roughly +26% from $23.11. Buyers look set to stay in control over this stretch.
Expect ENOV to range from $24.07 to $54.91 through 2031. The $34.91 average target implies a +51% move from current prices. That is up +20% on the projected 2030 average. Momentum favours further upside here.
The ENOV price prediction for 2032 points to an average of $39.06 (low $26.32, high $62.81) — a potential gain of +69% on today's $23.11. Buyers look set to stay in control over this stretch.
In 2033, ENOV is projected to trade between $28.01 and $69.69, averaging $42.47 — a potential gain of +84% from today's $23.11. That is up +9% on the projected 2032 average. Momentum favours further upside here.
Enovis Corporation's 2034 outlook centres on $41.14, within a $26.58 to $68.77 range. That is -3% versus the projected 2033 average. That marks a +78% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, ENOV could reach as high as $68.81, with a base case around $40.46 and support toward $25.63 — roughly +75% from $23.11. Momentum favours further upside here.
Expect ENOV to range from $36.26 to $114.54 through 2040. The $62.70 average target implies a +171% move from current prices. That is up +55% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The ENOV price prediction for 2050 points to an average of $122.11 (low $60.00, high $247.35) — a potential gain of +428% on today's $23.11. Momentum favours further upside here.
Investing $1,000 in ENOV today (≈ 43.271311 ENOV) could be worth
$5,284.03
+$4,284.03 (+428%) by 2050 · US Dollar
Based on the average projected ENOV price of $122.11 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ENOVwould be worth at today's price.
$1,000 invested in ENOV on May 27, 2025 (≈ 29.904307 ENOV) would be worth
$691.09
-$308.91 (-30.9%) today · 0.69× · US Dollar
Based on a ENOV entry price of $33.44 vs. today's $23.11.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $26.46 | $873.39 | -12.7% |
| 1 month ago | $24.54 | $941.73 | -5.8% |
| 3 months ago | $25.42 | $909.13 | -9.1% |
| 6 months ago | $30.27 | $763.46 | -23.7% |
| 1 year ago | $33.44 | $691.09 | -30.9% |
| All time (5.0y) ago | $78.07 | $296.01 | -70.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ENOV forecast.
Our base-case forecast reaches $46.00 around 2040.
Implied market cap at $46.00: $2.65B
Forecasts show a bullish trajectory beyond 2026. The 2030 average price is $31.12 with ROI of 28.6 and a bullish sentiment. The path of growth continues into 2031-2035, with 2031 avg $37.59 (ROI 55.4), 2032 avg $41.66 (ROI 72.2), 2033 avg $45.81 (ROI 89.4), 2034 avg $44.07 (ROI 82.2), and 2035 avg $43.04 (ROI 77.9).
The 2040 forecast points to an average of $67.89 (ROI 180.7) with a bullish sentiment, and by 2050 the average is projected at $132.98 (ROI 449.7) with sustained bullishness. These are estimates, not guarantees, and carry risks including market volatility and sector dynamics.
Tap a question to reveal the answer.
The 2030 forecast shows an avg of $31.12 with ROI of 28.6 and sentiment BULLISH.
Forecasts indicate a shift from neutral in 2026 (avg $24.19, ROI 0) to bullish long-term, with higher averages and ROIs in 2030-2050; however, these are estimates, not guarantees.
The 2040 max forecast is $124.91, and the 2050 average is $132.98, suggesting upside beyond $100 is possible in the forecast horizon. These are estimates, not guarantees.
Current price is $24.19 and market cap is $1.39B.
The 30-day range is from $19.22 to $30.45.
Enovis Corporation Community Discussion
0Share your Enovis Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.